뒤로
Alterity Therapeutics Limited(PRNAF) 가격
PRNAF 주가 차트
PRNAF 수입
Alterity Therapeutics Limited
$0
0%
$0
오늘 기준:Feb 11, 13:32:17 GMT-5
Earnings FAQ
PRNAF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Alterity Therapeutics Limited PRNAF의 지난 분기 매출 실적은 어땠나요?
Alterity Therapeutics Limited의 매출 추정치는 얼마인가요?
Alterity Therapeutics Limited의 수익 품질 점수는 얼마인가요?
Alterity Therapeutics Limited는 언제 수익을 보고하나요?
Alterity Therapeutics Limited의 예상 수익은 얼마인가요?
Alterity Therapeutics Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0097
시가
$0.0097
일일 범위
$0.0097 - $0.0097
52주 범위
$0.003 - $0.0139
거래량
10.0K
평균 거래량
336
EPS(TTM)
0.00
배당수익률
--
시가총액
$105.4M
Alterity Therapeutics Limited란 무엇인가요?
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.